logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme Says EMA Accepts Oral Teriflunomide MAA To Treat Multiple Sclerosis

Genzyme, a Sanofi company (SNY), announced the European Medicines Agency, or EMA, has accepted the filing of the marketing authorization application, or MAA, for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis, or MS.

The company noted that the purpose of the MAA is to secure approval to market and allow prescription of teriflunomide in the European Union based on data from two completed pivotal Phase III trials, TEMSO and TENERE. These trials represent two of five efficacy studies of teriflunomide in MS that are completed or underway, making the clinical program one of the largest and broadest of any MS therapy in development.

An application to market teriflunomide in the United States is under review by the U.S. Food & Drug Administration.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Alphabet Inc. (GOOG, GOOGL), the parent company of Google, Thursday reported an increase in profit for the first quarter, driven largely revenue growth in search and advertising. Alphabet's first-quarter profit rose to $5.43 billion or $7.73 per share from $4.21 billion or $6.02 per share last year. On... A passenger was booted from a Delta Air Lines flight after an emergency run to the bathroom while the plane was delayed for almost two hours on the tarmac, according to media reports. Kima Hamilton, 39, reportedly said that he needed to use the restroom while the plane was on the tarmac in Atlanta en route to Milwaukee on April 18. McDonald's is going to discontinue a popular item that has been on the menu for decades - the Hi-C Orange Lavaburst - from May 1, according to a memo posted on Reditt. With customers having only a few more days to get their hands on the iconic, popular beverage before its gone forever, McDonald's is already facing a backlash for its decision.
comments powered by Disqus
Follow RTT